Retatrutide Bloodwork Guide: What Labs to Track (2026)
Retatrutide bloodwork guide: track HbA1c, lipase, calcitonin, and lipids with optimal ranges and testing timeline.
Retatrutide Bloodwork Guide: What to Track and Why
Retatrutide is a triple-receptor agonist — it activates GIP, GLP-1, and glucagon receptors simultaneously. That makes it one of the most metabolically active compounds in the peptide space, with profound effects on blood sugar, insulin sensitivity, lipids, liver fat, and body composition.
It also means there's more to monitor. GLP-1 receptor agonists carry known risks around pancreatic inflammation and thyroid C-cell concerns. The glucagon receptor component adds another metabolic lever. Bloodwork isn't optional here — it's how you confirm the protocol is working and catch problems before they become serious.
This guide covers exactly which labs to run, when to run them, and what the numbers mean.
The Testing Timeline
Baseline (before starting): Run all the tests below 1-2 weeks before your first dose. This is your reference point.
Dose escalation check (week 8-12): Retest fasting glucose, lipase, and liver enzymes. You're ramping doses during this period — this catches pancreatic or hepatic stress early.
Mid-protocol (week 16-20): Retest metabolic markers (HbA1c, fasting insulin, HOMA-IR) and lipid panel. By now you should see meaningful metabolic shifts.
Post-protocol (2-4 weeks after finishing): Retest everything. This tells you what improvements persist after discontinuation.
Biomarkers at a Glance
Click any bar to jump to the full breakdown.
Tier 1: Core Metabolic Markers
These biomarkers directly measure what retatrutide is designed to do — improve glycemic control and insulin sensitivity. The phase 2 trial demonstrated dose-dependent reductions in HbA1c and fasting glucose.
HbA1c (Glycated Hemoglobin)
What it measures: Your average blood sugar over the past 2-3 months. Glucose molecules attach to hemoglobin in red blood cells — the more glucose in your blood, the higher the percentage.
Why it matters for retatrutide: This is your primary efficacy marker. Retatrutide's GLP-1 and GIP receptor activation directly enhances insulin secretion and glucose disposal. The phase 2 trial showed HbA1c reductions of up to 2.02% in participants with type 2 diabetes.
High-performance target: Below 5.0% if non-diabetic. Below 5.4% is excellent for metabolic health optimization.
Fasting Glucose
What it measures: Blood sugar after an overnight fast (8-12 hours). This is your snapshot of glucose regulation at rest.
Why it matters: Fasting glucose responds faster than HbA1c — you can see changes within 2-4 weeks. It's your early signal that retatrutide is affecting glucose metabolism.
Fasting Insulin
What it measures: Insulin levels after an overnight fast. High fasting insulin indicates your pancreas is working overtime to keep glucose in range — a sign of insulin resistance even when glucose looks normal.
Why it matters: Retatrutide should reduce insulin resistance, meaning your pancreas needs to produce less insulin to maintain glucose control. Falling fasting insulin with stable glucose is the ideal response pattern.
HOMA-IR (Calculated)
What it measures: A calculated estimate of insulin resistance using fasting glucose and fasting insulin: (Glucose x Insulin) / 405.
Why it matters: HOMA-IR combines glucose and insulin into a single insulin resistance score. It's more informative than either marker alone. You want this trending downward throughout your protocol.
Top Retatrutide Vendors
Ranked by price, COA availability, and reputation
Tier 2: Lipid Panel
Retatrutide's triple-receptor mechanism has significant effects on lipid metabolism. The GLP-1 component reduces hepatic lipogenesis, the glucagon component increases fatty acid oxidation, and the GIP component modulates lipid storage. The phase 2 obesity trial showed meaningful improvements across the lipid panel.
Total Cholesterol
What it measures: The combined total of LDL, HDL, and VLDL cholesterol in your blood.
LDL Cholesterol
What it measures: "Bad" cholesterol — the particles that deposit in arterial walls. Lower is generally better, but particle count (LDL-P) matters more than concentration.
HDL Cholesterol
What it measures: "Good" cholesterol — particles that transport cholesterol back to the liver for disposal. Higher is better.
Triglycerides
What it measures: Fat in the bloodstream, primarily influenced by carbohydrate intake and insulin resistance. Triglycerides are one of the markers most responsive to GLP-1 agonist therapy.
ApoB
What it measures: The number of atherogenic lipoprotein particles in your blood. Each LDL, VLDL, and lipoprotein(a) particle carries exactly one ApoB molecule, making it a more accurate measure of cardiovascular risk than LDL-C alone.
Why track it with retatrutide: ApoB is the single best predictor of cardiovascular risk. As retatrutide improves metabolic health, ApoB should trend downward alongside triglycerides and LDL.
Tier 3: Liver and Pancreatic Safety
GLP-1 receptor agonists have been associated with pancreatitis in rare cases. Retatrutide's glucagon receptor activity adds a hepatic component. These markers ensure the liver and pancreas are handling the metabolic shifts safely.
ALT (Alanine Aminotransferase)
What it measures: A liver enzyme released when liver cells are damaged. It's the most specific marker for liver injury.
Why it matters: Retatrutide can reduce liver fat (a positive effect), but any compound that significantly alters hepatic metabolism warrants liver monitoring.
AST (Aspartate Aminotransferase)
What it measures: Another liver enzyme, though less specific than ALT — it's also found in heart and muscle tissue.
Interpreting the pair: If both ALT and AST rise, it's likely hepatic. If AST rises alone, consider muscle damage from exercise. The AST/ALT ratio above 2:1 may indicate more serious liver pathology.
GGT (Gamma-Glutamyl Transferase)
What it measures: A liver enzyme involved in glutathione metabolism. Sensitive to bile duct issues and oxidative stress.
Why track it: GGT adds granularity to liver assessment. An elevated GGT with normal ALT/AST may indicate bile duct stress or metabolic burden that ALT alone would miss.
Lipase
What it measures: A pancreatic enzyme that breaks down fats. Elevated lipase indicates pancreatic inflammation or injury.
Why it matters for retatrutide: This is your critical safety marker. GLP-1 receptor agonists carry a known (though rare) risk of pancreatitis. Lipase above 3x the upper limit of normal with abdominal symptoms warrants immediate medical attention.
Amylase
What it measures: An enzyme produced by the pancreas and salivary glands that breaks down starch. Like lipase, elevation indicates pancreatic stress.
The pair matters: Lipase is more specific for pancreatitis than amylase. If both are elevated, the signal is stronger. If only amylase is elevated, it could be salivary rather than pancreatic.
Tier 4: Thyroid and General Safety
GLP-1 receptor agonists carry a boxed warning for thyroid C-cell tumors based on rodent studies. While this has not been confirmed in humans, monitoring thyroid markers is standard practice. Retatrutide's triple-receptor mechanism makes comprehensive safety monitoring especially important.
TSH (Thyroid Stimulating Hormone)
What it measures: The pituitary's signal to the thyroid. High TSH means the thyroid is underperforming; low TSH means it's overactive.
Free T4
What it measures: The active, unbound form of the thyroid hormone thyroxine. This is what actually drives metabolic rate.
Why track both: TSH and free T4 together paint the full thyroid picture. TSH alone can be misleading — it can be "normal" while T4 is shifting.
Calcitonin
What it measures: A hormone produced by thyroid C-cells. Elevated calcitonin can indicate C-cell hyperplasia or medullary thyroid carcinoma.
Why it matters for retatrutide: GLP-1 receptor agonists caused thyroid C-cell tumors in rodents, leading to a boxed warning. In humans, the clinical significance is unclear, but baseline and periodic calcitonin monitoring is recommended — especially with prolonged use.
Action thresholds: Calcitonin above 50 pg/mL warrants further evaluation. Above 100 pg/mL requires imaging and specialist referral regardless of symptoms.
CBC and CMP
Complete Blood Count (CBC) checks red blood cells, white blood cells, and platelets. Comprehensive Metabolic Panel (CMP) covers 14 markers including kidney function (BUN, creatinine), electrolytes, and glucose.
These won't tell you if retatrutide is "working," but they make sure it's not causing problems. Run these at baseline and post-protocol.
How to Order Labs
You don't need a doctor's visit for every test:
- Direct-to-consumer labs: HealthLabs.com lets you order bloodwork without a prescription or insurance. Order online, walk into any of 4,500+ LabCorp or Quest draw sites, and get results in 1-2 business days.
- Your primary care doctor: If you have a good relationship with your doctor, ask them to add these to your regular bloodwork. HbA1c, CBC, CMP, and lipid panels are routine and often covered by insurance.
- Endocrinologist: For calcitonin and thyroid monitoring, an endocrinologist may be more appropriate, particularly if you have thyroid history.
Budget-conscious approach: If you can only afford a few tests, prioritize in this order:
- HbA1c + fasting glucose + fasting insulin (about $30-50 direct)
- Lipase (about $15-25 — your critical safety marker)
- Lipid panel + liver enzymes (usually bundled for $25-40)
- Calcitonin (about $30-50 — baseline at minimum)
Putting It All Together: Sample Protocol
Week -1 (Baseline): Run HbA1c, fasting glucose, fasting insulin, lipid panel, liver enzymes (ALT, AST, GGT), lipase, amylase, TSH, free T4, calcitonin, CBC, CMP. This is your "before" snapshot.
Week 8-12 (Escalation check): Retest fasting glucose, lipase, ALT, AST. You're ramping doses — this catches problems early. Add calcitonin if concerned about thyroid.
Week 16-20 (Mid-protocol): Retest HbA1c, fasting insulin, HOMA-IR, lipid panel. These slower-moving markers should show meaningful shifts by now.
Week 24+ (Post-protocol): Retest everything from baseline. Compare each marker to your starting numbers. Document what changed and by how much.
What to do with results: If metabolic markers improved (lower HbA1c, better lipids, falling HOMA-IR) and safety markers are stable, the protocol is working as intended. If lipase is elevated or calcitonin is trending up, consult a healthcare provider before continuing.
Related Reading
-
Retatrutide Dosing Guide — titration schedules and protocols
-
Retatrutide Reconstitution Guide — step-by-step mixing and dilution charts
-
Semaglutide Bloodwork Guide — biomarker tracking for another GLP-1 agonist
-
Semaglutide Reconstitution Guide — mixing guide for semaglutide
-
BPC-157 Bloodwork Guide — different biomarker profile for healing peptides
-
MOTS-C Bloodwork Guide — metabolic and mitochondrial markers
References
- Jastreboff, A.M., et al. (2023). Triple-hormone-receptor agonist retatrutide for obesity — a phase 2 trial. New England Journal of Medicine, 389(6), 514-526. PMID:37366315
- Rosenstock, J., et al. (2023). Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial. The Lancet, 402(10401), 529-544. PMID:37385280
- Sanyal, A.J., et al. (2024). Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial. Nature Medicine, 30, 2037-2048. PMID:38858523
- Bezin, J., et al. (2023). GLP-1 receptor agonists and the risk of thyroid cancer. Diabetes Care, 46(2), 384-390. PMC8294388
This guide is for educational and informational purposes only. It is not medical advice. Retatrutide is sold as a research compound and is not FDA-approved for human use. The biomarker ranges described here reflect optimization targets used in functional and sports medicine — they are not diagnostic criteria. Lab results should be interpreted by a qualified healthcare provider in the context of your full medical history. The Peptide Catalog is not responsible for medical decisions made based on information presented here. HealthLabs.com links are affiliate links — we may earn a commission at no additional cost to you.